Cutanos and Pfizer team up to apply LC-TDS technology to autoimmune diseases

Thanks to Pfizer’s Emerging Science Fund, Cutanos will explore its immune cell-specific drug delivery system as a potential therapy platform for autoimmune disorders. In the next two years, this joint project aims to show induction of tolerance against self-antigens. Innovative therapeutic solutions in autoimmunity are one of the biggest unmet medical needs worldwide.

—